Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
09/05/2022 12:26
May 9 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX ANNOUNCES TYPE C MEETING WITH FDA FOR CORAL, A
PHASE
3 HIGH-RISK COVID-19 OUTPATIENT STUDY
* RESVERLOGIX CORP - MEETING IS SCHEDULED FOR EARLY AUGUST
* RESVERLOGIX CORP - ADVANCEMENT TO PHASE 3 TRIAL WILL
TARGET
OUTPATIENTS WITH MULTIPLE RISK FACTORS FOR SERIOUS OUTCOMES
* RESVERLOGIX - WILL CONCLUDE ITS PHASE 2 TRIAL IN
HOSPITALIZED
COVID-19 PATIENTS EARLY, THUS FOCUSING ITS RESOURCES ON ADVANCED
PHASE 3 PROGRAM
Source text for Eikon: ID:nGNXb8rdh
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment